VPC
Vestal Point Capital Portfolio holdings
AUM
$1.9B
This Quarter Return
+7.59%
1 Year Return
-12.28%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$1.27B
AUM Growth
+$1.27B
(-5.5%)
Cap. Flow
-$177M
Cap. Flow
% of AUM
-13.98%
Top 10 Holdings %
Top 10 Hldgs %
50.64%
Holding
85
New
23
Increased
22
Reduced
17
Closed
16
Top Buys
| 1 |
Insmed
INSM
|
$62.1M |
| 2 |
NARI
Inari Medical, Inc. Common Stock
NARI
|
$49.5M |
| 3 |
Agios Pharmaceuticals
AGIO
|
$33.8M |
| 4 |
BioMarin Pharmaceuticals
BMRN
|
$28.1M |
| 5 |
Structure Therapeutics
GPCR
|
$25.9M |
Top Sells
| 1 |
Ascendis Pharma
ASND
|
$74.7M |
| 2 |
Jazz Pharmaceuticals
JAZZ
|
$66.8M |
| 3 |
Globus Medical
GMED
|
$61.6M |
| 4 |
Ultragenyx Pharmaceutical
RARE
|
$58.3M |
| 5 |
ONC
BeOne Medicines Ltd. American Depositary Shares
ONC
|
$49.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Bristol-Myers Squibb
BMY
$96.5B
| $12.9M | 0.98% |
250,000
-250,000
| -50% | -$12.9M |
|
27
GSK
GSK
$78.5B
| $12.3M | 0.93% |
+300,000
| New | +$12.3M |
|
|
BCAX
28
Bicara Therapeutics Inc. Common Stock
BCAX
$651M
| $10.8M | 0.82% |
+425,000
| New | +$10.8M |
|
29
Dianthus Therapeutics
DNTH
$759M
| $10.8M | 0.82% |
395,000
-205,000
| -34% | -$5.61M |
|
30
Crinetics Pharmaceuticals
CRNX
$3.14B
| $10.5M | 0.79% |
+205,000
| New | +$10.5M |
|
|
ITOS
31
DELISTED
iTeos Therapeutics
ITOS
| $10.5M | 0.79% |
1,025,000
-725,000
| -41% | -$7.4M |
|
32
Applied Therapeutics
APLT
$74.9M
| $9.73M | 0.74% |
1,145,000
-4,285,000
| -79% | -$36.4M |
|
33
Nurix Therapeutics
NRIX
$696M
| $9.55M | 0.72% |
425,000
-75,000
| -15% | -$1.69M |
|
34
Sanofi
SNY
$121B
| $8.64M | 0.66% |
+150,000
| New | +$8.64M |
|
35
Bruker
BRKR
$5.04B
| $8.63M | 0.65% |
+125,000
| New | +$8.63M |
|
36
Apogee Therapeutics
APGE
$2.17B
| $8.02M | 0.61% |
+136,500
| New | +$8.02M |
|
37
Zymeworks
ZYME
$1.12B
| $7.72M | 0.59% |
615,000
+175,000
| +40% | +$2.2M |
|
38
Lexeo Therapeutics
LXEO
$259M
| $7.68M | 0.58% |
850,000
+10,000
| +1% | +$90.4K |
|
39
Tarsus Pharmaceuticals
TARS
$2.47B
| $7.56M | 0.57% |
+230,000
| New | +$7.56M |
|
40
Alto Neuroscience
ANRO
$99.6M
| $7.44M | 0.56% |
650,000
+30,000
| +5% | +$343K |
|
41
Becton Dickinson
BDX
$55.3B
| $7.23M | 0.55% |
+30,000
| New | +$7.23M |
|
42
Madrigal Pharmaceuticals
MDGL
$9.76B
| $6.37M | 0.48% |
+30,000
| New | +$6.37M |
|
43
Legend Biotech
LEGN
$6.41B
| $6.09M | 0.46% |
+125,000
| New | +$6.09M |
|
44
Fate Therapeutics
FATE
$119M
| $5.9M | 0.45% |
1,685,000
-315,000
| -16% | -$1.1M |
|
45
Galapagos
GLPG
$2.05B
| $5.18M | 0.39% |
180,000
| – | – |
|
46
UroGen Pharma
URGN
$904M
| $5.08M | 0.39% |
+400,000
| New | +$5.08M |
|
47
Monte Rosa Therapeutics
GLUE
$296M
| $4.93M | 0.37% |
930,000
+40,000
| +4% | +$212K |
|
48
Geron
GERN
$938M
| $4.77M | 0.36% |
+1,050,000
| New | +$4.77M |
|
49
Passage Bio
PASG
$22.7M
| $4.27M | 0.32% |
6,100,000
+48,000
| +0.8% | +$33.6K |
|
50
Allogene Therapeutics
ALLO
$249M
| $4.2M | 0.32% |
1,500,000
-700,000
| -32% | -$1.96M |
|